Seaport Therapeutics Q2 Cash Surges to $427M, Pipeline Advances with Multiple Data Readouts Ahead
SPTX sits 38% above its 52-week low of $14.85.
Summary
Seaport Therapeutics reported Q2 2026 results with a cash position of $427.3 million, more than doubling from $212.6 million in Q1, following its upsized IPO. The company expects this runway to fund operations into 2029, well past key clinical milestones. Enrollment in the Phase 2b BUOY-1 trial of GlyphAllo in major depressive disorder is on track, with topline data expected in the first half of 2027. A Phase 1 driving simulation trial for GlyphAllo is also on track to report data in the second half of 2026. Positive Phase 1 proof-of-concept data for GlyphAgo in generalized anxiety disorder supports advancing to Phase 2a in the second half of 2026 and Phase 2b in the first half of 2027. The novel Glyph2BLSD program is progressing toward first-in-human-enabling studies by the end of 2027. This follows the Q1 report in June, which highlighted a strong cash position and clinical progress, but the Q2 update provides a materially stronger balance sheet and clearer timelines for multiple near-term catalysts.
At the time of this announcement, SPTX was trading at $20.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.85 to $22.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.